10.1038/s41419-018-0865-6 - A patient-derived xenograft pre-clini...

This document has been corrected

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma

10.1038/s41419-018-0865-6

Published Online: 2018-07-24

Journal: Cell Death & Disease•Publisher: Springer Science and Business Media LLC

Authors: Berglind O. Einarsdottir•Elin M. V. Söderberg•Elisa Funck-Brentano•Erik Larsson•Henrik Jespersen•Joakim Karlsson•Jonas A. Nilsson•Lars Ny•Lisa M. Nilsson•Louise Carstam•Martin Scobie•Mattias F. Lindberg•Olof Wallner•Roger Olofsson Bagge•Siggeir F. Brynjolfsson•Thomas Helleday•Tobias Koolmeister•Ulrika Stierner•Ulrika Warpman Berglund

This document has been corrected

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma

10.1038/s41419-018-0865-6

Published Online: 2018-07-24

Journal: Cell Death & Disease

NOW

2020-02-06•Correction

Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma

10.1038/s41419-020-2301-y

* information provided by CrossRef

2020-02-06•Correction

10.1038/s41419-020-2301-y

* information provided by CrossRef

2018-07-24•Published

2020-02-06•Correction

Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma

10.1038/s41419-020-2301-y

* information provided by CrossRef

This document has been corrected

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma

10.1038/s41419-018-0865-6

Published Online: 2018-07-24

Journal: Cell Death & Disease•Publisher: Springer Science and Business Media LLC